RKV Rakovina Therapeutics Inc.

0.1084USD0.1550 CAD · TSXV+6.90%Mkt Cap: 2.65M USDP/E: —

Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments that target DNA-damage response systems. It develops kt-2000 series, which are patented class…

Key Statistics

Company
Market Cap2.65M USD
Enterprise Value5.06M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-6.07M USD
Revenue/Share—
Last Price0.1084 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISINCA75103L3092
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-1.23
EV/Revenue—
P/S—
P/B-1.74
EPS (TTM)-0.22 USD
EPS (Forward)—
52W Range
0.059430% of range0.2238
52W High0.2238 USD
52W Low0.0594 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-6212.61%
ROA-204.71%
ROIC-268.59%
ROCE-642.13%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.07M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-30.04%
Net Debt2.42M USD
Net Debt/EBITDA-0.59
Net Debt/FCF—
Balance Sheet
Debt/Equity18.58
Current Ratio0.15
Quick Ratio0.10
Book Value/Sh-0.06 USD
Cash/Share0.0056 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJun 24, 2025
Analyst Consensus
Rating—
Target (Mean)0.1748 USD
Upside (mean)+61.3%
Target Range0.1748 USD – 0.1748 USD
# Analysts1
Ownership
Shares Out.24.41M
Float21.54M
Insiders5.68%
Institutions0.00%
Short Interest
Short Ratio2.3d
Short % Out.0.06%
Shares Short15.80K
Short (prev mo.)2.95K
Technical
SMA 500.1486 (-27.1%)
SMA 2000.1088 (-0.4%)
Beta-0.27
S&P 52W Chg12.00%
Avg Vol (30d)7.53K
Avg Vol (10d)7.59K
Technical Indicators
RSI (14)40.7
MACD-0.0138
MACD Signal-0.0116
MACD Hist.-0.0022
BB Upper0.1419 USD
BB Middle0.1213 USD
BB Lower0.1008 USD
BB Width33.89%
ATR (14)0.0129 USD
Vol Ratio (20d)0.51x

About Rakovina Therapeutics (CVE: RKV)

›

Rakovina Therapeutics (CVE: RKV) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.

The shares were at 0.1550 CAD on 19 November 2026, down 38.0% over 52 weeks. Its 52-week range is 0.0850 CAD to 0.3200 CAD: the price is 51.6% below the high and 82.4% above the low.

Its market capitalisation is 3.78M CAD.

Rakovina Therapeutics reports an operating margin of 0.0%.

Its debt exceeds its cash by 3.46M CAD, a debt-to-equity ratio of 18.58. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 0.2500 CAD is 61.3% above the current price. The next earnings report is expected on 26 November 2026.